Can a 60-second injection revolutionize cancer care for thousands?
In short: For many cancer patients, treatment is a marathon of hours spent in hospital chairs. New advancements are shifting this paradigm, moving toward rapid-delivery immunotherapies and precision compounds that target the genetic signals of tumors without damaging the healthy cells that keep us alive.
The NHS in England has begun rolling out a new injectable form of pembrolizumab, a well-known immunotherapy. This 'rapid' jab can be administered in just 60 seconds, replacing intravenous (IV) infusions that previously took up to 2 hours per session. This shift represents a 90% reduction in treatment time for patients. The medication works by triggering the body's own immune cells to recognize and destroy cancer cells. It is currently being used to treat 14 different types of cancer, including lung, breast, head and neck, and cervical cancers.
For the approximately 14,000 patients in England who start pembrolizumab therapy annually, this means significantly less time in treatment units and more time spent at home. From a logistical standpoint, the move to a ready-to-administer subcutaneous injection removes the need for pharmacy teams to prepare sterile IV bags, thereby increasing hospital capacity and productivity. While the rapid jab optimizes delivery, a separate breakthrough from the Francis Crick Institute and Vividion Therapeutics addresses the underlying mechanics of tumor growth.
They have identified chemical compounds that target the RAS gene, which is mutated in roughly one in five cancers. In these mutations, RAS becomes permanently active, constantly signaling cells to divide. Historically, blocking RAS or its associated enzymes, like PI3K, was difficult because those same pathways are essential for normal functions—for example, PI3K helps regulate blood sugar. Blocking it entirely can cause severe side effects like hyperglycemia. A study released within Science on 9 October highlights tiny molecules which bind indefinitely to the PI3K exterior close to the RAS docking area. This allows the researchers to block the specific interaction that drives tumors while leaving the enzyme free to perform its other vital roles, such as insulin signaling. In mouse studies involving RAS-mutated lung tumors, these compounds successfully stopped tumor growth without causing elevated blood sugar levels. These two advancements—one in delivery efficiency and one in molecular precision—represent major steps toward more manageable and safer cancer therapies.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Two New Groundbreaking Cancer Treatments
- Also: NHS England » ‘1-minute’ immunotherapy jab rolled out on NHS for tens of thousands with cancer
- Also: Breakthrough cancer therapy stops tumor growth without harming healthy cells
To cite this card, link to https://intellectplus.co.uk/app/science-two-new-groundbreaking-cancer-treatments.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics
